Micheal West
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1841346152
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $592 and has fallen 52.4% since, to $282 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in DC, where the typical reported total is $1,085.
Across 62 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$165
- Antares Pharma, Inc.$136
- AbbVie$127
- Amneal Pharmaceuticals LLC$123
- Pfizer$80
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$77
- plus $376 from 14 others
What the payments were for
- Food & beverage$1,084100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $165 |
| Antares Pharma, Inc. | 8 | $136 |
| AbbVie | 7 | $127 |
| Amneal Pharmaceuticals LLC | 7 | $123 |
| Pfizer | 3 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $77 |
| Merck | 4 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Novo Nordisk | 3 | $41 |
| Corcept Therapeutics | 2 | $38 |
| Bayer | 1 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| Gilead | 1 | $27 |
| Radius Health, Inc. | 1 | $24 |
| Covidien LP | 1 | $18 |
| Amgen | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Mannkind Corporation | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$1,084 in reported general payments places this provider in the 45th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $134,090 |
| JardianceEmpagliflozin | 73 | $94,447 |
| MounjaroTirzepatide | 51 | $57,583 |
| TrulicityDulaglutide | 20 | $40,473 |
| JanuviaSitagliptin Phosphate | 31 | $35,859 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $21,436 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $17,679 |
| FarxigaDapagliflozin Propanediol | 13 | $17,027 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $13,332 |
| Testosterone | 26 | $7,161 |
| Novolog FlexpenInsulin Aspart | 21 | $6,007 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $4,607 |
| SynthroidLevothyroxine Sodium | 29 | $2,722 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $2,035 |
| Metformin Hcl ErMetformin Hcl | 112 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $41 | $134,09061 claims |
| Lilly USA, LLCMounjaro, Trulicity | $165 | $98,05671 claims |
| Boehringer IngelheimJardiance | $34 | $94,44773 claims |
| MerckJanuvia, Janumet Xr | $49 | $57,29547 claims |
| AstraZenecaFarxiga | $12 | $17,02713 claims |
| AbbVieSynthroid | $127 | $2,72229 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $123 | $82979 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.